Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CHKA | P35790 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18721319 | 0.86 | ALDH1A1 (0.53) | ALDH1A1MAPTATMHTTKDM4E | |
| SCHEMBL13548292 | 0.85 | ALDH1A1 (0.49) | ALDH1A1MAPTATMHTTKDM4E | |
| SCHEMBL26860189 | 0.83 | MET (0.39) | ALDH1A1MAPTATMHTTKDM4E | |
| SCHEMBL28091363 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MAPTATMHTTKDM4E | |
| SCHEMBL29903898 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MAPTATMHTTKDM4E | |
| SCHEMBL5528688 | 0.81 | ALDH1A1 (0.55) | ALDH1A1MAPTATMHTTKDM4E | |
| SCHEMBL11833 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MAPTATMHTTKDM4E | |
| SCHEMBL12251089 | 0.80 | NPC1 (0.50) | ALDH1A1MAPTATMHTTKDM4E | |
| SCHEMBL22951475 | 0.79 | ALDH1A1 (0.52) | ALDH1A1MAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL17886955 | 0.79 | ALDH1A1 (0.49) | ALDH1A1MAPTATMHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2023-12-05 | — | — | US | disclosed |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | ALDH1A1 3319/4885MAPT 4521/4885ATM 3943/4885 |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | ALDH1A1 3515/4885MAPT 2371/4885ATM 3449/4885 |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | ALDH1A1 2970/4885MAPT 4552/4885ATM 4025/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | ALDH1A1 1555/4885MAPT 3123/4885ATM 4765/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ALDH1A1 148/4885MAPT 1563/4885ATM 4350/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | ALDH1A1 319/4885MAPT 3807/4885ATM 3836/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | ALDH1A1 3986/4885MAPT 4336/4885ATM 4568/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | ALDH1A1 3689/4885MAPT 2827/4885ATM 4358/4885 |
| US-20230373972-A1 | PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | F7, F11, HABP2 | ALDH1A1 1218/4885MAPT 4565/4885ATM 4598/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | ALDH1A1 876/4885MAPT 4132/4885ATM 2990/4885 |
| US-11833122-B2 | Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases | KEAP1, GOT2, COL1A1 | ALDH1A1 106/4885MAPT 3640/4885ATM 97/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | ALDH1A1 2017/4885MAPT 1163/4885ATM 1447/4885 |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | PCK1, PDK2, PDK1 | ALDH1A1 1403/4885MAPT 2067/4885ATM 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.